Docstoc

Nutritional Prevention and Treatment of Osteoporosis

Document Sample
Nutritional Prevention and Treatment of Osteoporosis Powered By Docstoc
					                   Nutritional Prevention and Treatment of Osteoporosis
                                                By Maureen Williams, ND

The human skeleton’s 206 bones provide the basic structural frame for the rest of the body. The compact or hard bone
includes the mineralized portion of bone. It represents most of the bone mass, and provides the strength the skeleton needs
to support the body. The trabecular or soft bone houses the cells responsible for bone remodeling: osteoclasts resorb bone
by removing minerals and breaking up collagen; osteoblasts build bone by laying down new collagen and mineralizing the
collagen matrix. The balance of osteoclast and osteoblast activities shifts in favor of bone resorption as we age, and
particularly in women after menopause. The result is a reduction in bone mineral density, or osteopenia, which can
eventually lead to osteoporosis and increased risk of fracture.

In women, most bone loss occurs during the first eight to ten years after menopause. During this critical window, a
number of things can be done to slow bone loss, including staying physically active, not smoking, and eating a diet rich in
fruits and vegetables, high in legumes including soy, sufficient in omega-3 fatty acids like those in fish, moderate in
animal protein, and low in sugar, sodium, caffeine, soft drinks, and alcohol. In addition, a number of nutritional
supplements have been found to support bone mineralization through their effects on calcium metabolism.

Calcium - Calcium is the most substantial mineral component of structural bone. In addition to dairy foods, there are
many dietary sources of calcium, including green vegetables, beans, soy foods, nuts and seeds, blackstrap molasses, figs,
sea vegetables, and bony fish. Findings from some studies suggest that getting adequate dietary calcium might prevent
bone loss and fractures, i but there is no conclusive evidence linking dairy foods—the main source of calcium in the
standard American diet—to bone health. ii iii

Calcium supplements have long been recommended as a way to boost calcium intake, which is notoriously low in many
subsets of Americans. Supplementing with calcium and vitamin D has been associated with increased bone mineral
density in peri- and postmenopausal women, iv v shorter healing time in women with osteoporosis-related upper arm
fractures, vi and reduced bone loss in men and women over the age of 60. vii The combination of calcium and vitamin D
was also found to reduce the fracture rate in elderly people living at a Northern latitude, viii and to prevent tooth loss in
people over 65. ix

It is important to note that supplementing with calcium alone does not appear to have a significant fracture-preventing
effect. x xi The most recent report from the ongoing National Health and Nutrition Examination Survey (NHANES)
presented findings showing no clear correlation between calcium intake and fracture risk. xii Even with vitamin D,
supplementation appears to be of little value in women with adequate calcium intake and normal blood levels of vitamin
D. xiii In light of the growing body of evidence that other nutrients influence calcium metabolism and bone cell activity in
critical and complex ways, researchers have begun to question whether the current calcium supplement recommendations
are too high. xiv xv

Calcium from carbonate and citrate are the most common forms of calcium supplements. Calcium carbonate, the most
cost-effective form, is well-absorbed and tolerated in most individuals when taken with a meal (ensures optimal
absorption). Calcium carbonate supplements provide greater amounts of elemental calcium and consequently require
fewer tablets than other forms of calcium. Calcium citrate can be taken with or without food and may be the supplement
of choice for individuals with achlorhydria or who are taking stomach acid blocking drugs (histamine-2 blockers or proton
pump inhibitors). Calcium citrate should be used in individuals with inflammatory bowel disease, or absorption disorders.
xvi xvii



Vitamin D3/Cholecalciferol - Vitamin D3 (cholecalciferol) is produced in sun-exposed skin and activated through a
series of chemical reactions that take place in the liver and kidneys. Once in its active form, calcitriol, it raises calcium
levels by increasing calcium absorption in the intestines and resorption in the kidneys. It also modulates bone remodeling
by osteoclasts and osteoblasts.

Vitamin D2 (ergocalciferol) is not produced by humans, but in some sun-exposed invertrebrates, fungi, and plants. While
vitamin D2 is often used in nutritional supplements and is able to raise blood levels of 25-hydroxyvitamin D (25(OH)D,


                                                                                                                           9‐09
the standard measure of vitamin D status), supplementing with vitamin D3 appears to be more effective at improving
vitamin D status. xviii

Supplementing with vitamin D3 plus calcium reduced bone loss and nonvertebral fracture incidence in community
dwelling elders in one study, xix but had no effect on fracture risk in another study. xx An increase in bone mineral density
and reduction in bone loss was observed in people who had experienced an osteoporosis-related hip fracture and
subsequently supplemented with vitamin D3 plus calcium. xxi Researchers conducting a meta-analysis noted a trend
toward a reduced risk of falling in postmenopausal women taking vitamin D3. xxii

Low and deficient vitamin D levels are highly prevalent in people who avoid sun exposure due to health concerns or
cultural traditions, use sunscreen, have dark skin, or live in northern latitudes. In a study involving North American
women with osteoporosis, 52% were found to have suboptimal vitamin D status (<30 ng/ml 25(OH)D). xxiii Because
vitamin D insufficiency has been linked to increased risks of osteoporosis and other chronic diseases including heart
disease, diabetes, and cancer, new recommendations for vitamin D supplementation are being considered. xxiv xxv A routine
recommendation of 1,000 IU per day is considered safe and reasonable, xxvi xxvii and higher amounts are likely indicated for
people with osteoporosis or known vitamin D insufficiency. xxviii

Magnesium - Magnesium, often thought of as the counterpart to calcium, is found in foods such as nuts, seeds, whole
grains, and legumes. It functions primarily intracellularly, and interacts closely with the other cationic minerals, such that
magnesium deficiency can cause hypocalcaemia and hypokalaemia, xxix overly high calcium intake can cause a relative or
absolute magnesium deficiency, xxx and low potassium intake (generally due to lack of fruits and vegetables in the diet)
can lead to increased excretion of calcium and magnesium. xxxi xxxii Women with osteoporosis have been found to have low
intracellular xxxiii and serum xxxiv xxxv magnesium levels, and chronically low magnesium levels have also been associated
with diabetes, hypertension, and coronary artery disease. xxxvi Low magnesium intake is common xxxvii and has been
associated with lower bone mineral density in Caucasians xxxviii and a higher risk of hip fracture in a Japanese community.
xxxix
       People with high magnesium intake have been found to have higher bone mineral density and less bone loss over time
than people with low intake. xl xli In preliminary trials, increasing dietary magnesium xlii and magnesium supplementation
xliii
      have both been found to improve bone mineral density in postmenopausal women with osteoporosis.

Most nutritional guidelines recommend a 2:1 ratio of calcium to magnesium, as it is believed that an excessively high
calcium intake can disrupt the balance between calcium and magnesium, increasing the risk of cardiovascular
consequences such as hypertension and thrombosis. xliv Given magnesium’s important role in thrombus prevention as well
as maintaining healthy blood pressure, regular heart rhythm, and normal cardiac muscle function, xlv an induced relative
magnesium deficiency could explain the increased incidence of cardiovascular disease seen in women using calcium and
calcium plus vitamin D in some xlvi xlvii (though not all xlviii ) studies.

Boron - Humans have a trace requirement for the mineral, boron, which is found in fruits, vegetables, and nuts. Although
its role in the body is not fully understood, boron appears to help regulate the levels of other minerals, including calcium,
magnesium, and phosphorus. A low-boron diet has been linked to increased urinary excretion of both calcium and
magnesium, while supplemental boron seems to limit these mineral losses. xlix l li Boron has also been found to reduce
urinary calcium loss in people with a magnesium-deficient diet. lii The need for boron appears to be enhanced in cases of
magnesium, potassium, and vitamin D deficiencies. liii

Lysine - The essential amino acid, lysine, is a necessary nutrient for the synthesis of biochemical proteins including
muscle tissue, hormones, antibodies, and enzymes. In addition, lysine increases calcium absorption and reduces urinary
calcium excretion, leading to an overall positive impact on calcium balance. liv Research using bone cells derived from
osteopenic rats suggests that lysine stimulates osteoblast proliferation and activity, and might thereby promote bone
building. lv lvi This may partially explain the negative impact of a low-protein diet on bone health. lvii lviii

By increasing calcium absorption and osteoblast activity, lysine might be useful in treating osteoporosis. In two controlled
trials, calcitonin plus a combination of lysine, arginine, and lactose was found to improve bone mineral density and reduce
bone loss more than calcitonin alone in elderly people with osteoporosis. lix lx

Horsetail (Equisetum arvense) - Horsetail is a common weed in many parts of the United States. In traditional herbal
medicine, it is used in the treatment of urinary tract infections, hemorrhage and bleeding, superficial wounds, and benign

                                                                                                                         9‐09
prostatic hyperplasia. It is know to be rich in antioxidant phenolic compounds lxi as well as minerals. lxii In particular, the
stems of horsetail contain high levels of silica and silicic acids, lxiii which support bone and collagen formation.

Women and men with high dietary intake of silicon have higher bone density than women with low intake. lxiv
Supplementing with silicon led to improved hip bone density in women with osteoporosis, lxv and augmented the bone-
building effects of calcium plus vitamin D in women with osteopenia. lxvi Horsetail extract, in a preliminary trial, was
more effective at increasing bone density than a calcium/silicon combination taken by women over the course of one year.
lxvii



Strontium - Strontium is a metal element that occurs naturally in the form of the mineral, strontianite. A compound made
with strontium and ranelic acid (strontium ranelate) has been developed and marketed in Europe and other parts of the
world as a drug for the treatment of osteoporosis. This drug is not available in the US or Canada, but strontium salts, such
as strontium citrate and strontium carbonate, are increasingly common ingredients in bone-building nutritional
supplements.

In vitro research suggests that strontium becomes incorporated into the bone mineral crystal matrix. lxviii Strontium also
appears to stimulate the production of mature osteoblasts and inhibit osteoclast formation and activity in the trabecular
bone, increasing the capacity of bone to lay down mineralized matrix. lxix lxx

Strontium ranelate has been subjected to a number of clinical trials and has been found to be safe and effective for the
treatment of osteopenia and osteoporosis. lxxi One study identified the minimum effective dose for improving bone mineral
density to be 1 gram per day. lxxii It has also been shown to significantly reduce the incidence of vertebral (approximately
24–40% reduction) and non-vertebral (approximately 15% reduction) fractures over study periods of three to five years,
particularly in women at high risk for fracture and women over 80 years old. lxxiii lxxiv lxxv lxxvi lxxvii In postmenopausal
women with osteoporosis, strontium use has been associated with better physical and emotional functioning, less pain, and
higher overall quality of life. lxxviii Strontium ranelate has also been found to prevent cartilage loss associated with
osteoarthritis, lxxix and reduce back pain in people with spinal osteoarthritis. lxxx
References:
i
  Heaney RP. Calcium, dairy products and osteoporosis. J Am Coll Nutr 2000;19:83S-99S.
ii
    Alvarez-León EE, Román-Viñas B, Serra-Majem L. Dairy products and health: a review of the epidemiological evidence. Br J Nutr 2006;96:S94-9.
iii
    Lanou AJ, Berkow SE, Barnard ND. Calcium, dairy products, bone health in children and young adults: a reevaluation of the evidence. Pediatrics 2005;115:736-43.
iv
    Di Daniele N, Carbonelli MG, Candeloro N, et al. Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and
post-menopause women; a double-blind, randomized, controlled trial. Pharmacol Res 2004;50:637-41.
v
    Baeksgaard L, Andersen KP, Hyldstrup L. Calcium and vitamin D increases spinal BMD in healthy, postmenopausal women. Osteoporos Int 1998;8:255-60.
vi
    Doetsch AM, Faber J, Lynnerup N, et al. The effect of calcium and vitamin D3 supplementation on the healing of the proximal humerus fracture: a randomized
placebo-controlled study. Calcif Tissue Int 2004;75:183-8.
vii
     Peacock M, Liu G, Carey M, et al. Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J
Clin Endocrinol Metab 2000;85:3011-9.
viii
     Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic
population-based 3-year intervention study. J Bone Miner Res 2004;19:370-8.
ix
    Krall EA, Wehler C, Garcia RI, et al. Calcium and vitamin D supplements reduce tooth loss in the elderly. Am J Med 2001;111:452-6.
x
    Shea B, Wells G, Cranney A, et al. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 2004;(1):CD004526.
xi
    Reid IR, Bolland MJ, Grey A. Effect of calcium supplementation on hip fractures. Osteoporos Int 2008;19:1119-23.
xii
     Zhong Y, Okoro CA, Balluz LS. Association of total calcium and dietary protein intakes with fracture risk in postmenopausal women: the 1999-2002 National Health
and Nutrition Examination Survey (NHANES). Nutrition 2009;25:647-54.
xiii
     Tfelt-Hansen J, Tørring O. Calcium and vitamin D3 supplements in calcium and vitamin D3 sufficient early postmenopausal healthy women. Eur J Clin Nutr
2004;58:1420-4.
xiv
     Roux C, Bischoff-Ferrari HA, Papapoulos SE, et al. New insights into the role of vitamin D and calcium in osteoporosis management: an expert roundtable
discussion. Curr Med Res Opin 2008;24:1363-70.
xv
     Reid IR, Bolland MJ, Grey A. Effect of calcium supplementation on hip fractures. Osteoporos Int 2008;19:1119-23.
xvi
     Straub DA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract 2007;22:286-96.
xvii
      Reinwald S, Weaver CM, Kester JJ. The health benefits of calcium citrate malate: a review of the supporting science. Adv Food Nutr Res 2008;54:219-346.
xviii
      Trang HM, Cole DE, Rubin LA, et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr
1998;68:854-8.
xix
     Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N
Engl J Med 1997;337:670-6.
xx
     Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation
of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005;365:1621-8.
xxi
     Hitz MF, Jensen JE, Eskildsen PC. Bone mineral density and bone markers in patients with a recent low-energy fracture: effect of 1 y of treatment with calcium and
vitamin D. Am J Clin Nutr 2007;86:251-9.
xxii
      Jackson C, Gaugris S, Sen SS, Hosking D. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. QJM 2007;100:185-92.
xxiii
      Holick MF, Siris ES, Binkley N, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin
Endocrinol Metab 2005;90:3215-24.
xxiv
      Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol 2008;3:1535-41.

                                                                                                                                                                9‐09
xxv
      Cherniack EP, Levis S, Troen BR. Hypovitaminosis D: a widespread epidemic. Geriatrics 2008;63:24-30.
xxvi
       Binkley N, Krueger D, Drezner MK. Low vitamin D status: time to recognize and correct a Wisconsin epidemic. WMJ 2007;106:466-72.
xxvii
       Linnebur SA, Vondracek SF, Vande Griend JP, et al. Prevalence of vitamin D insufficiency in elderly ambulatory outpatients in Denver, Colorado. Am J Geriatr
Pharmacother 2007;5:1-8.
xxviii
        Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging 2007;24:1017-29.
xxix
       Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev 2003;24:47-66.
xxx
      Seelig MS. Increased need for magnesium with the use of combined oestrogen and calcium for osteoporosis treatment. Magnes Res 1990;3:197-215.
xxxi
       Rylander R, Remer T, Berkemeyer S, Vormann J. Acid-base status affects renal magnesium losses in healthy, elderly persons. J Nutr 2006;136:2374-7.
xxxii
       Macdonald HM, New SA, Fraser WD, et al. Low dietary potassium intakes and high dietary estimates of net endogenous acid production are associated with low
bone mineral density in premenopausal women and increased markers of bone resorption in postmenopausal women. Am J Clin Nutr 2005;81:923-33.
xxxiii
        Odabasi E, Turan M, Aydin A, et al. Magnesium, zinc, copper, manganese, and selenium levels in postmenopausal women with osteoporosis. Can magnesium play
a key role in osteoporosis? Ann Acad Med Singapore 2008;37:564-7.
xxxiv
        Mutlu M, Argun M, Kilic E, et al. Magnesium, zinc and copper status in osteoporotic, osteopenic and normal post-menopausal women. J Int Med Res 2007;35:692-
5.
xxxv
       Reginster JY, Strause L, Deroisy R, et al. Preliminary report of decreased serum magnesium in postmenopausal osteoporosis. Magnesium 1989;8:106-9.
xxxvi
        Swaminathan R. Magnesium metabolism and its disorders. Clin Biochem Rev 2003;24:47-66.
xxxvii
        Rude RK, Gruber HE. Magnesium deficiency and osteoporosis: animal and human observations. J Nutr Biochem 2004;15:710-6.
xxxviii
         Ryder KM, Shorr RI, Bush AJ, et al. Magnesium intake from food and supplements is associated with bone mineral density in healthy older white subjects. J Am
Geriatr Soc 2005;53:1875-80.
xxxix
        Yaegashi Y, Onoda T, Tanno K, et al. Association of hip fracture incidence and intake of calcium, magnesium, vitamin D, and vitamin K. Eur J Epidemiol
2008;23:219-25.
xl
     Tucker KL, Hannan MT, Kiel DP. The acid-base hypothesis: diet and bone in the Framingham Osteoporosis Study. Eur J Nutr 2001;40:231-7.
xli
     Tucker KL, Hannan MT, Chen H, et al. Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and
women. Am J Clin Nutr 1999;69:727-36.
xlii
      Abraham GE, Grewal H. A total dietary program emphasizing magnesium instead of calcium. Effect on the mineral density of calcaneous bone in postmenopausal
women on hormonal therapy. J Reprod Med 1990;35:503-7.
xliii
      Stendig-Lindberg G, Tepper R, Leichter I. Trabecular bone density in a two year controlled trial of peroral magnesium in osteoporosis. Magnes Res 1993;6:155-63.
xliv
      Seelig MS. Increased need for magnesium with the use of combined oestrogen and calcium for osteoporosis treatment. Magnes Res 1990;3:197-215.
xlv
      Gums JG. Magnesium in cardiovascular and other disorders. Am J Health Syst Pharm 2004;61:1569-76.
xlvi
      Pentti K, Tuppurainen MT, Honkanen R, et al. Use of calcium supplements and the risk of coronary heart disease in 52-62-year-old women: The Kuopio
Osteoporosis Risk Factor and Prevention Study. Maturitas 2009;63:73-8.
xlvii
       Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ
2008;336:262-6.
xlviii
       Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007;115:846-54.
xlix
      Nielsen FH. Studies on the relationship between boron and magnesium which possibly affects the formation and maintenance of bones. Magnes Trace Elem
1990;9:61-9.
l
   Nielsen FH. Biochemical and physiologic consequences of boron deprivation in humans. Environ Health Perspect 1994;102 Suppl 7:59-63.
li
    Nielsen FH, et al. Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women. FASEB J 1987;1:394-7.
lii
     Hunt CD, Herbel JL, Nielsen FH. Metabolic responses of postmenopausal women to supplemental dietary boron and aluminum during usual and low magnesium
intake: boron, calcium, and magnesium absorption and retention and blood mineral concentrations. Am J Clin Nutr 1997;65:803-13.
liii
     Schaafsma A, de Vries PJ, Saris WH. Delay of natural bone loss by higher intakes of specific minerals and vitamins. Crit Rev Food Sci Nutr 2001;41:225-49.
liv
     Civitelli R, Villareal DT, Agnusdei D, et al. Dietary L-lysine and calcium metabolism in humans. Nutrition 1992;8:400-5.
lv
     Fini M, Torricelli P, Giavaresi G, et al. Effect of L-lysine, arginine on primary osteoblast cultures from normal and osteopenic rats. Biomed Pharmacother
2001;55:213-20.
lvi
     Conconi MT, Tommasini M, Muratori E, Parnigotto PP. Essential amino acids increase the growth and alkaline phosphatase activity in osteoblasts cultured in vitro.
Farmaco 2001;56:755-61.
lvii
      Kerstetter JE, O'Brien KO, Insogna KL. Dietary protein, calcium metabolism, and skeletal homeostasis revisited. Am J Clin Nutr 2003;78:584S-592S. Review.
lviii
      Bonjour JP. Dietary protein: an essential nutrient for bone health. J Am Coll Nutr 2005;24:526S-36S.
lix
     Bellati U, Liberati M. Experience regarding the use of arginine-lysine-lactose treatment in menopausal osteoporosis. Minerva Med 1994;85:327-32. [in Italian]
lx
     Abate G, Taormina F, Brillante C, Fraccalaglio L. The effects of the carbocalcitonin + arginine-lysine-lactose combination in senile involutional osteoporosis.
Minerva Med 1994;85:253-9. [in Italian]
lxi
     Mimica-Dukic N, Simin N, Cvejic J, et al. Phenolic compounds in field horsetail (Equisetum arvense L.) as natural antioxidants. Molecules 2008;13:1455-64.
lxii
      Raczuk J, Biardzka E, Daruk J. The content of Ca, Mg, Fe and Cu in selected species of herbs and herb infusions. Rocz Panstw Zakl Hig 2008;59:33-40. [in Polish]
lxiii
      Holzhüter G, Narayanan K, Gerber T. Structure of silica in Equisetum arvense. Anal Bioanal Chem 2003;376:512-7.
lxiv
      Jugdaohsingh R, Tucker KL, Qiao N, et al. Dietary silicon intake is positively associated with bone mineral density in men and premenopausal women of the
Framingham Offspring cohort. J Bone Miner Res 2004;19:297-307.
lxv
      Eisinger J, Clairet D. Effects of silicon, fluoride, etidronate and magnesium on bone mineral density: a retrospective study. Magnes Res 1993;6:247-9.
lxvi
      Spector TD, Calomme MR, Anderson SH, et al. Choline-stabilized orthosilicic acid supplementation as an adjunct to calcium/vitamin D3 stimulates markers of bone
formation in osteopenic females: a randomized, placebo-controlled trial. BMC Musculoskelet Disord 2008;9:85.
lxvii
       Corletto F. [Female climacteric osteoporosis therapy with titrated horsetail (Equisetum arvense) extract plus calcium (osteosil calcium): randomized double blind
study]. Miner Ortoped Traumatol 1999;50:201-206.
lxviii
       Li ZY, Lam WM, Yang C, et al. Chemical composition, crystal size and lattice structural changes after incorporation of strontium into biomimetic apatite.
Biomaterials 2007;28:1452-60.
lxix
      Brennan T, Rybchyn M, Green W, et al. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 2009:online ahead of print.
lxx
      Bonnelye E, Chabadel A, Saltel F, Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and
resorption in vitro. Bone 2008;42:129-38.
lxxi
      Neuprez A, Hiligsmann M, Scholtissen S, et al. Strontium ranelate: The first agent of a new therapeutic class in osteoporosis. Adv Ther 2008;25:1235-56.
lxxii
       Reginster JY, Deroisy R, Dougados M, et al. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-
ranging, placebo-controlled PREVOS trial. Osteoporos Int 2002;13:925-31.
lxxiii
       Roux C, Reginster JY, Fechtenbaum J, et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of
baseline risk factors. J Bone Miner Res 2006;21:536-42.
lxxiv
       Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis:
Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22.
lxxv
       Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone
Miner Res 2006;21:1113-20.

                                                                                                                                                                   9‐09
lxxvi
       Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal
osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:1687-95.
lxxvii
        Collette J, Bruyère O, Kaufman JM, et al. Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover. Osteoporos Int
2009:online publication ahead of print.
lxxviii
        Marquis P, Roux C, de la Loge C, et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis.
Osteoporos Int 2008;19:503-10.
lxxix
       Alexandersen P, Karsdal MA, Qvist P, et al. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women.
Bone 2007;40:218-22.
lxxx
      Bruyere O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008;67:335-9.




                                                                                                                                                                     9‐09